SCHEMBL3986441

SCHEMBL3986441

CNC(=O)c1cc(Oc2cccc(CCNC(=O)c3cccc(OC)c3)c2)ccn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.55
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52
ALDH1A1 P00352 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
NPC1 O15118 2/20 0.50
RAF1 P04049 1/20 0.50
BRAF P15056 1/20 0.50
KDM4E B2RXH2 1/20 0.50
MMP13 P45452 1/20 0.50
PARP1 P09874 1/20 0.50
ROCK2 O75116 1/20 0.49
ROCK1 Q13464 1/20 0.49
AURKA O14965 1/20 0.49
HPGD P15428 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14266590 0.93 KDR (0.53) RAB9AALDH1A1SMN1; SMN2NPC1RAF1
SCHEMBL4289196 0.92 RAB9A (0.55) RAB9ACA1CA2CA7CA9
SCHEMBL3992512 0.91 CA1 (0.54) RAB9ACA1CA2CA7CA9
SCHEMBL3986457 0.90 NPC1 (0.56) RAB9ASMN1; SMN2NPC1RAF1BRAF
SCHEMBL14266595 0.90 RAB9A (0.58) RAB9AALDH1A1NPC1RAF1BRAF
SCHEMBL14266607 0.89 BRAF (0.53) RAB9ASMN1; SMN2NPC1RAF1BRAF
SCHEMBL3989052 0.89 BRAF (0.49) RAB9ACA1CA2CA7CA9
SCHEMBL14266553 0.89 BRAF (0.55) RAB9ACA1CA2CA7CA9
SCHEMBL3987745 0.89 RAF1 (0.54) RAF1BRAFROCK2ROCK1AURKA
SCHEMBL3991948 0.88 KDM5B (0.51) RAB9ACA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061761-A1 PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY Millennium Pharmaceuticals, Inc. (US) 2009-05-27 EP disclosed
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 US disclosed
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 US disclosed
WO-2008030448-A1 PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 WO disclosed
WO-2008030448-A1 PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MAP4K5, MAP3K5, MAP4K2 RAB9A 1730/4885CA1 4235/4885CA2 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.